Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NeOnc Technologies Holdings, Inc. ( (NTHI) ) just unveiled an update.
On April 14, 2026, NeOnc Technologies Holdings, Inc. reported that Chairman and CEO Amir Heshmatpour bought roughly $300,000 of company stock in the prior week, signaling management’s confidence as it approaches key milestones for its CNS cancer drugs NEO100 and NEO212. The company also disclosed that its 2025 net loss of about $62 million was dominated by $45.2 million of non-cash stock-based compensation and one-time listing-related advisory fees, implying normalized cash operating expenses of approximately $10.1 million and positioning, supported by a $13 million private placement in early 2026, to advance its Phase 2 programs amid encouraging early efficacy data in difficult-to-treat brain tumors.
NEO212 has completed Phase 1 with a recommended Phase 2 dose set and early signs of possible durable disease control in heavily pretreated glioblastoma and brain metastasis patients, while NEO100’s fully enrolled Phase 2a trial in IDH1-mutant recurrent high-grade glioma follows data suggesting higher remission and progression-free survival rates versus historical salvage therapies. Management’s emphasis on disciplined capital allocation, non-GAAP normalized expense metrics, and debt reduction, alongside clinical results and exploratory ultrasound combinations for NEO100, underscores a strategy to strengthen NeOnc’s financial footing and enhance its competitive position in CNS oncology as it advances toward potentially pivotal studies.
Spark’s Take on NTHI Stock
According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral.
The score is primarily constrained by very weak financial performance (minimal revenue, large losses, accelerating cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Corporate events provide some offset via positive clinical milestones and added financing/liquidity actions, but not enough to overcome the current financial and trend risks.
To see Spark’s full report on NTHI stock, click here.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing central nervous system therapeutics designed to overcome the blood-brain barrier. Its NEO drug development platform has generated novel chemotherapy agents, including NEO100 and NEO212, which are in Phase II clinical trials for malignant gliomas and other CNS cancers and benefit from FDA Fast-Track and IND status, underpinned by patents licensed from the University of Southern California.
The company’s proprietary portfolio, protected by patents extending to 2038, targets oncological and neurological conditions with CNS-penetrant therapies and innovative delivery methods. Its candidates have shown positive signals in laboratory studies and early-stage clinical trials, including potential durable efficacy in recurrent IDH1-mutant gliomas and differentiation versus standard temozolomide-based treatments.
Average Trading Volume: 50,490
Technical Sentiment Signal: Strong Sell
Current Market Cap: $128.5M
See more data about NTHI stock on TipRanks’ Stock Analysis page.